Other anti-VEGF monoclonal antibody, bevacizumab, is shown to have prognostic benefit even after the progression of prior combination therapy with bevacizumab, so called bevacizumab beyond progression in colorectal cancer [27]. The gene discussed is VEGFA; the disease is colorectal cancer.